Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Expected to Rise, Piper Sandler Analyst Says

Karyopharm Therapeutics (NASDAQ:KPTI) had its price target boosted by investment analysts at Piper Sandler from $4.00 to $5.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s target price points to a potential upside of 466.76% from the stock’s previous close.

A number of other research analysts also recently commented on KPTI. StockNews.com raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Royal Bank of Canada restated an “outperform” rating and set a $3.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. Finally, Robert W. Baird dropped their target price on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Price Performance

KPTI stock opened at $0.88 on Wednesday. The stock’s 50 day moving average is $0.81 and its two-hundred day moving average is $0.91. Karyopharm Therapeutics has a 52-week low of $0.62 and a 52-week high of $1.95. The company has a market capitalization of $109.99 million, a PE ratio of -0.75 and a beta of 0.16.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.01. The company had revenue of $38.78 million for the quarter, compared to analyst estimates of $37.86 million. During the same period in the prior year, the business earned ($0.30) earnings per share. As a group, sell-side analysts anticipate that Karyopharm Therapeutics will post -0.95 EPS for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP boosted its holdings in shares of Karyopharm Therapeutics by 80.6% during the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after acquiring an additional 792,283 shares during the period. AQR Capital Management LLC lifted its position in Karyopharm Therapeutics by 494.5% in the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after purchasing an additional 622,194 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Karyopharm Therapeutics during the 2nd quarter valued at about $494,000. Acadian Asset Management LLC bought a new position in Karyopharm Therapeutics in the 2nd quarter worth about $167,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Karyopharm Therapeutics in the second quarter valued at approximately $143,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).